IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

MLA

Emma Alecock, et al. “IL-6 Receptor Inhibition with Tocilizumab Improves Treatment Outcomes in Patients with Rheumatoid Arthritis Refractory to Anti-Tumour Necrosis Factor Biologicals: Results from a 24-Week Multicentre Randomised Placebo-Controlled Trial.” Annals of the Rheumatic Diseases, vol. 67, July 2008, pp. 1516–23. EBSCOhost, https://doi.org/10.1136/ard.2008.092932.

APA

Emma Alecock, A Cantagrel, R. van Vollenhoven, Janet S. Lee, Joel M. Kremer, Paul Emery, A Sanchez, Edward C. Keystone, & Hans-Peter Tony. (2008). IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 67, 1516–1523. https://doi.org/10.1136/ard.2008.092932

Chicago

Emma Alecock, A Cantagrel, R. van Vollenhoven, Janet S. Lee, Joel M. Kremer, Paul Emery, A Sanchez, Edward C. Keystone, and Hans-Peter Tony. 2008. “IL-6 Receptor Inhibition with Tocilizumab Improves Treatment Outcomes in Patients with Rheumatoid Arthritis Refractory to Anti-Tumour Necrosis Factor Biologicals: Results from a 24-Week Multicentre Randomised Placebo-Controlled Trial.” Annals of the Rheumatic Diseases 67 (July): 1516–23. doi:10.1136/ard.2008.092932.